Abstract
OBJECTIVES
The purposes of this study is to estimate the cost of cancer care after its diagnosis and to identify factors that can influence the cost of cancer care. METHODS: The study subjects were patients with an initial diagnosis one of four selected tumors and had their first two-years of cancer care at a national cancer center. The data were obtained from medical records and patient surveys. We classified cancer care costs into medical and nonmedical costs, and each cost was analyzed for burden type, medical service, and cancer stage according to cancer types. Factors affecting cancer care costs for the initial phase included demographic variables, socioeconomic status and clinical variables. RESULTS: Cancer care costs for the initial year following diagnosis were higher than the costs for the following successive year after diagnosis. Lung cancer (25,648,000 won) had higher costs than the other three cancer types. Of the total costs, patent burden was more than 50% and medical costs accounted for more than 60%. Inpatient costs accounted for more than 60% of the medical costs for stomach and liver cancer in the initial phase. Care for late-stage cancer was more expensive than care for early-stage cancer. Nonmedical costs were estimated to be between 4,500,000 to 6,000,000 won with expenses for the caregiver being the highest. The factors affecting cancer care costs were treatment type and cancer stage. CONCLUSIONS: The cancer care costs after diagnosis are substantial and vary by cancer site, cancer stage and treatment type. It is useful for policy makers and researchers to identify tumor-specific medical and nonmedical costs. The effort to reduce cancer costs and early detection for cancer can reduce the burden to society and improve quality of life for the cancer patients.
Citations
Citations to this article as recorded by
- Projecting Lifetime Health Outcomes and Costs Associated with the Ambient Fine Particulate Matter Exposure among Adult Women in Korea
Gyeyoung Choi, Yujeong Kim, Gyeongseon Shin, SeungJin Bae
International Journal of Environmental Research and Public Health.2022; 19(5): 2494. CrossRef - Expenditure and Financial Burden for Stomach Cancer Diagnosis and Treatment in China: A Multicenter Study
Kai Zhang, Jian Yin, Huiyao Huang, Le Wang, Lanwei Guo, Jufang Shi, Min Dai
Frontiers in Public Health.2020;[Epub] CrossRef - Early Detection is Important to Reduce the Economic Burden of Gastric Cancer
Jie-Hyun Kim, Sung Soo Kim, Jeong Hoon Lee, Da Hyun Jung, Dae Young Cheung, Woo-Chul Chung, Soo-Heon Park
Journal of Gastric Cancer.2018; 18(1): 82. CrossRef - Supporting Low-income Cancer Patients: Recommendations for the Public Financial Aid Program in the Republic of Korea
Hye Sook Min, Hyung Kook Yang, Keeho Park
Cancer Research and Treatment.2018; 50(4): 1074. CrossRef - Modeling lifetime costs and health outcomes attributable to secondhand smoke exposure at home among Korean adult women
Jiyae Lee, Ah Ram Han, Dalwoong Choi, Kyung-Min Lim, SeungJin Bae
BMJ Open.2017; 7(5): e013292. CrossRef - The Relief Effect of Copayment Decreasing Policy on Unmet Needs in Targeted Diseases
Jae-Woo Choi, Jae-Hyun Kim, Eun-Cheol Park
Health Policy and Management.2014; 24(1): 24. CrossRef - Changes in Economic Status of Households Associated with Catastrophic Health Expenditures for Cancer in South Korea
Jae-Woo Choi, Kyoung-Hee Cho, Young Choi, Kyu-Tae Han, Jeoung-A Kwon, Eun-Cheol Park
Asian Pacific Journal of Cancer Prevention.2014; 15(6): 2713. CrossRef - Medicaid inpatient costs and nested structural analysis using a hierarchical linear modeling (HLM) approach
Keon-Hyung Lee, Sang-Chul Park, Jungwon Park, Seunghoo Lim
Health Services and Outcomes Research Methodology.2013; 13(2-4): 157. CrossRef - Costs During the First Five Years Following Cancer Diagnosis in Korea
Ji-Yeon Shin, So Young Kim, Kun-Sei Lee, Sang-Il Lee, Young Ko, Young-Soon Choi, Hong Gwan Seo, Joo-Hyuk Lee, Jong-Hyock Park
Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3767. CrossRef - Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan
Myung‐Ju AHN, Chun‐Ming TSAI, Te‐Chun HSIA, Elaine WRIGHT, John Wen‐Cheng CHANG, Heung Tae KIM, Joo‐Hang KIM, Jin Hyoung KANG, Sang‐We KIM, Eun‐Jin BAE, Mijeong KANG, Johanna LISTER, Stefan WALZER
Asia-Pacific Journal of Clinical Oncology.2011; 7(s2): 22. CrossRef